Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SNYNF save search
Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis
Published: 2023-03-21 (Crawled : 08:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.74%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.13%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.71%
H: 0.05%
C: -0.64%
dupixent children six dermatitis approved
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
Published: 2023-03-21 (Crawled : 08:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.74%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.13%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.71%
H: 0.05%
C: -0.64%
dupixent children six dermatitis approved
The Rise, Fall and Future of Novavax
Published: 2023-03-21 (Crawled : 05:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.74%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.13%
H: 0.0%
C: 0.0%
Innovent Announces Clinical Data of Multiple Trials Will be Presented at the AACR Annual Meeting 2023
Published: 2023-03-21 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.74%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.24%
H: 0.01%
C: -0.99%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.13%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.13%
H: 0.34%
C: -1.12%
trials meeting
Global Genital Herpes Treatment Market 2022-2032: Sector to Reach $5.05 Billion by 2032 at a 4.7% CAGR
Published: 2023-03-20 (Crawled : 00:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.94%
H: 0.82%
C: 0.82%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.74%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: -1.15%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 1.38%
H: 2.4%
C: 0.84%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.25%
H: 0.19%
C: 0.04%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.09%
H: 0.34%
C: 0.26%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.13%
H: 0.0%
C: 0.0%
treatment global market
Techdow USA Announces FDA Approval of Generic Lovenox®, (Enoxaparin Sodium – Preservative Free) In Prefilled Syringes
Published: 2023-03-20 (Crawled : 21:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.98%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
lovenox fda approval
BIC: Change in Board Composition - Appointment proposal of Carole Callebaut Piwnica as independent director
Published: 2023-03-20 (Crawled : 18:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.98%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
change proposal
BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications
Published: 2023-03-20 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.98%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -0.64%
H: 2.72%
C: 2.54%
antibody tumor collaboration
Dermatitis Global Market Research Report 2023: An $8.57 Billion Market by 2027 - Long-term Forecasts to 2032
Published: 2023-03-20 (Crawled : 11:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: -0.06%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.98%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -0.5%
H: 1.38%
C: 1.23%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.78%
H: 0.74%
C: 0.72%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 1.38%
H: 1.16%
C: 1.13%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.19%
H: 1.18%
C: 1.04%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
report dermatitis research global market
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
Published: 2023-03-18 (Crawled : 16:20) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
| Email alert
Add to watchlist
dupixent dermatitis show
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
Published: 2023-03-18 (Crawled : 16:20) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
| Email alert
Add to watchlist
dupixent dermatitis show
2023 Top Blacks in Healthcare Awards Announced
Published: 2023-03-17 (Crawled : 18:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
awards
Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a TrialACER-801 safe and well-tolerated but did not achieve statistically significant decrease in frequency or severity of hot flashes in postmenopausal women
Published: 2023-03-17 (Crawled : 17:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: -44.55%
H: 0.0%
C: 0.0%
acer-801 women topline therapeutics results
Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial
Published: 2023-03-17 (Crawled : 13:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: -44.55%
H: 0.0%
C: 0.0%
acer-801 topline trial therapeutics results
Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance
Published: 2023-03-16 (Crawled : 21:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
lantus commercial insurance sanofi
RNAi Therapeutics Global Market to 2027: Rising Utilization in Oncology Pharmaceuticals and Accelerating Growth Rates of Infectious Diseases Drives Growth
Published: 2023-03-16 (Crawled : 19:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
ABUS | $2.725 -0.18% -0.18% 930K
|
Health Technology
|
| O: 0.34%
H: 3.73%
C: 1.36%
pharmaceuticals global therapeutics growth market
1 in 3 pemphigoid patients not well-managed on current treatments (MARKETVUE® REPORT)
Published: 2023-03-16 (Crawled : 16:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.07%
H: 1.96%
C: 0.56%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.01%
H: 0.0%
C: 0.0%
marketvue
IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results
Published: 2023-03-16 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.07%
H: 1.96%
C: 0.56%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.01%
H: 0.0%
C: 0.0%
IMV | $0.8225 -2.74% 45K
|
Health Technology
|
| O: 0.0%
H: 1.75%
C: -4.42%
year update financial results
Pharming Group reports financial results for full year 2022
Published: 2023-03-16 (Crawled : 07:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.07%
H: 1.96%
C: 0.56%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.01%
H: 0.0%
C: 0.0%
year group financial
Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results
Published: 2023-03-16 (Crawled : 07:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.07%
H: 1.96%
C: 0.56%
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -1.4%
H: 0.03%
C: -0.08%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.01%
H: 0.0%
C: 0.0%
IPHA | $2.48 5.53% 5.24% 9.4K
|
Health Technology
|
| O: -6.11%
H: 3.54%
C: 0.69%
pharma conference year financial